News
We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
Wall Street stocks closed higher Monday as the U.S. and China accused one another of violating a 90-day trade truce they had ...
Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in ...
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback